Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension

Abstract

Background

Overweight and obesity are frequently associated with preventable death and have emerged as a major challenge to public health. There is an ongoing debate on the role of abdominal obesity and its value in predicting cardiovascular and renal outcomes. The present analysis evaluates the prevalence of microalbuminuria (MAU) and conventional cardiovascular risk factors in relation to measures of general and abdominal obesity.

Methods

In this multinational, observational study, 20828 hypertensive out-patients from 26 countries including Europe, North and Latin America, Middle East, and Asia were analyzed. Urinary dipstick screening for MAU was performed as well as data on patient demographics, anthropometric measures, cardiovascular risk factors, comorbid conditions, and cardiovascular drug therapy collected. MAU prevalence was determined by a stepwise logistic regression analysis with cardiovascular risk factors as univariate.

Results

In the univariate analysis, MAU prevalence systematically increased with body mass index (BMI) from 54.4% (1st tertial) to 62.1% (3rd tertial) (p < 0.0001), an increase which was also observed for waist circumference (WC). At any level of BMI, MAU increased with WC from 53.5%, 54.8%, and 55.0% (1st tertial of WC in all three BMI tertials) to 61.4%, 62.1%, and 64.0% (3rd tertial of WC in all BMI tertials) (p < 0.0001). In the multivariate analysis, WC, but not BMI was independently associated with MAU. Furthermore, overweight/obesity were associated with the presence of modifiable and nonmodifiable risk factors.

Conclusion

An abnormal WC, but not BMI appears to be independently associated with MAU, an early marker of cardiovascular and renal risk. Increasing WC confers an incremental risk for MAU at any level of BMI, underlining the prognostic importance of abdominal fat accumulation beyond general obesity.

Keywords:

• obesity
• abdominal
• microalbuminuria
• cardiovascular
• renal

Introduction

Obesity is frequently associated with preventable death and has emerged as a major health care challenge in the 21st century.¹ In 2004, an estimated 32% of US adults (>20 years old) were obese, 4.8% of which were morbidly obese.² In Europe, obesity prevalence in adults differs from country to country, ranging from 10%–25%.³ Furthermore, a global obesity epidemic in preschool children and adolescents seems to be underway⁴ and highlights the urgent need for prevention. Overweight and obesity are frequently and independently associated with minor adverse health conditions, such as gallbladder or fatty liver disease, but also with serious illnesses, such as cancer.^5,6 However, another major concern with obesity is cardiometabolic risk, frequently associated with atherosclerotic cardiovascular disease or diabetes.⁷ There is an ongoing discussion on the particular importance of abdominal obesity, associated with an accumulation of visceral fat tissue, as an important component of the metabolic syndrome and its associated complications.^8–10 The INTERHEART Trial has identified abdominal obesity as a major independent risk factor for myocardial infarction in a large multiethnic population.¹¹ Microalbuminuria (MAU), defined as urinary albumine excretion of 30–300 mg/24 hours (20–200 mg/L in the spot urine), is an established cardiovascular risk indicator in diabetes, hypertensive patients, and the general population, and has been shown to be associated with endothelial dysfunction and to be predictive for coronary artery disease, myocardial infarction, stroke, and all-cause mortality.¹² Furthermore, MAU predicts the progression of diabetic nephropathy and is associated with vascular disease, congestive heart failure, diastolic dysfunction, and arterial hypertension.^13–16 It was the aim of the present study, to evaluate the relationship between overweight and abdominal obesity with MAU and conventional cardiovascular risk factors in a large multiethnic hypertensive population. It was hypothesized, that abdominal obesity confers an incremental cardiovascular and renal risk which is independent of the presence of general obesity.

Methods

A large international, cross-sectional study was conducted in 2005/2006 in cardiology outpatient clinics in 26 countries worldwide as described previously.¹⁷ In brief, 21,794 patients, aged ≥18 years with currently treated or newly diagnosed arterial hypertension were enrolled into the study. In all patients, urinary dipstick screening was performed (Microalbustix^®; Bayer HealthCare, Basel, Switzerland) and prevalence of MAU, defined as an albumin excretion of 30, 80, or 150 mg/L, was determined. Furthermore, information on patient demographics, anthropometric measures, cardiovascular risk factors and co-morbid conditions as well as cardiovascular drug therapy were collected in case report form. In order to evaluate the association of overweight/obesity with the cardiovascular risk profile, patients were stratified into three tertials of body mass index (BMI) and the presence of conventional risk factors and cardiovascular drug therapy were evaluated for all three groups. The same analysis was performed in overweight patients (defined as BMI 25–30 kg/m²) for the low versus high tertial of waist circumference (WC). All analyses were performed as univariate analysis and descriptive statistics was applied. In order to determine the association of MAU with overweight/obesity and abdominal obesity, the population was again stratified into medians and tertials (for BMI and WC) and also according to established cut-off levels for BMI (<25, 25–30, >30 kg/m²) and WC (≤ 102 cm vs > 102 cm for men, ≤ 88 cm vs > 88 cm for women) and MAU prevalence as well as odds ratios (OR) for MAU for each of these measures alone or in combination was assessed as univariate analysis. Furthermore a multivariate logistic regression analysis was performed as described previously in order to evaluate the association of BMI and WC with MAU.¹⁷ For the analyses, SAS statistical software (version 9.1.3; SAS Institute, Cary, NC, USA) was used. Continuous variables are depicted as mean values with standard deviation (SD), categorical variables as percentages with 95% confidence intervals (95% CI). ORs are depicted with 95% CI. Ethics committee approval was obtained by all participating sites and informed consent forms were signed by all patients prior to study enrollment. The study was conducted according to the principles defined by the Declaration of Helsinki.

Results

Characteristics of the study population

The i-SEARCH study enrolled a total of 21,794 patients, out of which 20,868 patients were included in the present analysis. Patient-demographics, anthropometric measures, risk factor profile, comorbidities as well as cardiovascular pharmacotherapy were described elsewhere¹⁷ and are depicted in Table 1.

Table 1 Patient characteristics

	Parameter (mean/%)	Total population (n = 20,868)
Demographics	Male (%)	52.3
	Age (years)	62.4
Anthropometric measures	BMI (kg/m^2)	28.9
	WC (cm)	99.4
	WHR	0.95
Risk factors/markers	SBP (mm Hg)	149.1
	Family history of MI/CAD (%)	27.8
	Exercise <4 hours/week (%)	65.1
	Exercise >4 hours/week (%)	35.0
	Moderate (%)	92.5
	Strenuous (%)	7.5
	Never smoked (%)	54.0
	Current smoker (%)	14.2
	No of cigarettes/day	16.3
	Duration since stopped smoking (years)	14.8
	Known dyslipidemia (%)	46.3
	TC ≥ 5.17 mmol/L (%)	52.6
	HDL-C < 1.16 mmol/L (%)	37.2
	TG ≥ 1.69 mmol/L (%)	45.8
	Type 2 diabetes mellitus (%)	27.5
	Length of diabetes (yrs.)	7.9
	HbA1c (%)	6.8
	CRP (mg/dl)	0.9
Comorbidities	Heart failure (%)	5.8
	Atrial fibrillation (%)	8.3
	LVH (Sokol. > 35 mm)(%)	14.4
	CAD (%)	22.9
	History of MI (%)	53.4
	History of myocardial revascularization (% CAD)	57.8
	Ischemic stroke (%)	4.8
	TIA (%)	3.8
	Aortic Aneurysm (%)	1.4
	PAD (%)	4.2
Cardiovascular pharmacotherapy	Thiazides (%)	28.3
	Loop diuretics (%)	8.7
	Aldosterone antagonists (%)	2.7
	CCB (%)	32.7
	BB (%)	43.7
	ACEI (%)	38.5
	ARB (%)	32.6
	AB (%)	3.1
	Statins (%)	38.1
	Fibrates (%)	3.4
	ASA (%)	40.0
	Other antiplatelet drugs (%)	6.4
	Warfarin/Coumadin (%)	5.0
	Digitalis (%)	3.0
	Oral nitrates (%)	6.8
	Antiarrhythmics (%)	3.4
	≥1 Diabetes drug (%)	19.8

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; HbA_1c, glycated hemogobin; HDL-C, high-density lipoprotein-cholesterol; LVH, left ventricular hypertrophy; MI, myocardial infarction; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference; WHR, waist-to-hip ratio.

Description of cardiovascular risk factors and pharmacotherapy

When patients were stratified into three BMI tertials, mean WC increased with BMI from the low to the high tertial (88.7, 99.0, 110.6 cm, respectively). The overweight group (BMI 25–30 kg/m²) comprised a total of 43.6% of the overall population and there were more men and patients were slightly older in the high WC group (110.0 cm) as compared to the low WC group (87.3 cm). With increasing BMI, a systematic increase in the prevalence of cardiovascular risk factors/markers, such as systolic blood pressure (147.8, 148.7, 151.1 mm Hg, respectively), history of myocardial infarction/ coronary artery disease (24.9%, 28.3%, 30.3%, respectively), physical activity (40.0%, 34.7%, 25.8%, respectively), dyslipidemia (41.8%, 48.1%, 49.4%, respectively) and type 2 diabetes (16.1%, 21.5%, 31.2%, respectively) was found. The same systematic increase in risk factors/markers was seen in the overweight group when comparing the low and the high WC group. In line with the increase in cardiovascular risk, more patients received cardiovascular drug therapy with increasing BMI as well as increasing WC in the overweight group. However, in the overweight group, patients with a higher WC did not seem to receive more thiazides, calcium channel blockers (CCBs), or angiotensin receptor blockers (ARBs) (see Table 2).

Table 2 Patient characteristics by BMi tertial and Wc tertial (high vs low) in overweight patients (BMi 25–30 kg/m²)

	Parameter (mean/%)	BMI (kg/m^2)			BMI 25–30 kg/m^2
		1st tertial (N = 6948)	2nd tertial (N = 6969)	3rd tertial (N = 6951)	WC 1st tertial (N = 3090)	WC 3rd terital (N = 2169)
Demographics	Male (%)	49.9	57.8	49.0	35.3	77.3
	Age (years)	63.2	62.7	61.4	61.6	64.1
Anthropometr measures	BMI (kg/m^2)	23.9	28.2	34.6	27.0	28.1
	WC (cm)	88.7	99.0	110.6	87.3	110.0
Risk factors/markers	SBP (mm Hg)	147.8	148.7	151.1	147.9	149.4
	Family history of MI/CAD (%)	24.9	28.3	30.3	27.2	29.6
	Exercise >4 hours/week (%)	40.0	34.7	25.8	36.5	33.9
	Known dyslipidemia (%)	41.8	48.1	49.4	44.6	48.0
	TC ≥ 5.17 mmol/L (%)	50.7	52.3	55.0	54.4	51.5
	HDL-C < 1.16 mmol/L (%)	317	39.0	40.6	31.6	44.9
	TG ≥ 1.69 mmol/L (%)	38.8	45.5	52.8	41.4	50.4
	Type 2 diabetes mellitus (%)	16.1	21.5	31.2	16.6	23.2
Cardiovascular pharmacotherapy	Thiazides (%)	25.9	27.9	30.9	27.5	27.0
	Aldosterone antagonists (%)	2.5	2.2	3.4	2.1	2.7
	CCBs (%)	32.2	31.8	34.0	31.4	31.4
	BBs (%)	41.8	43.6	45.6	43.2	44.8
	ACEs (%)	36.3	38.4	40.8	33.9	41.2
	ARBs (%)	30.6	33.2	34.0	34.6	32.8
	ABs (%)	2.7	2.8	3.8	2.5	3.5
	Statins (%)	34.9	39.1	40.2	35.4	40.9

Abbreviations: Abs, alpha blockers; ACEs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BBs, beta blockers; BMI, body mass index; CAD, coronary artery disease; CCBs, calcium channel blockers; HDL-C, high-density lipoprotein-cholesterol; MI, myocardial infarction; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WC, waist circumference.

Prevalence of MAU in relation to BMI

When patients were stratified into medians and tertials of BMI and also three levels of BMI, there was a significant increase in the prevalence of MAU, with 55.6% (95% CI: 54.6, 56.5) in the low versus 61.2% (95% CI: 60.2, 62.1) in the high median (p < 0.0001), 54.4% (95% CI: 53.2, 55.6) in the 1st , 58.6% (95% CI: 57.5, 59.8) in the 2nd and 62.1% (95% CI: 60.9, 63.2) in the 3rd tertial (p < 0.0001) and 54.4% (95% CI: 52.9, 55.8), 57.6% (95% CI: 56.6, 58.6) and 61.9% (95% CI: 60.8, 63.0) in patients with a BMI of <25, 25–30, or >30 kg/m² BMI (p < 0.0001) (Figure 1).

Figure 1 Prevalence of MAU in relation to BMI.

Abbreviations: BMI, body mass index; MAU, microalbuminuria.

Prevalence of MAU in relation to WC

When patients were stratified into medians, tertials and according to absolute levels of WC, a similar increase in MAU was detected. MAU prevalence was 54.6% (95% CI: 53.6, 55.6) in the low versus 62.1% (95% CI: 61.1, 63.0) in the high median (p < 0.0001), 53.9% (95% CI: 52.7, 55.1) in the 1st, 57.4% (95% CI: 56.2, 58.6) in the 2nd and 63.4% (95% CI: 62.3, 64.5) in the 3rd tertiale (p < 0.0001). In male patients with a WC ≤ 102 versus > 102 cm, MAU prevalence was 59.0% (95% CI: 57.7, 60.3) and 64.7% (95% CI: 63.3, 66.0), respectively (p < 0.0001), whereas in women, overall prevalence was markedly lower with 50.3% (95% CI: 48.5, 52.1) in the group with a waistline of ≤88 cm and 56.9% (95% CI: 55.7, 58.1) in women with a waistline of > 88 cm (p < 0.0001) (Figure 2).

Figure 2 Prevalence of MAU in relation to WC.

Abbreviations: MAU, microalbuminuria; WC, waist circumference.

Prevalence of MAU in relation to WC at different levels of BMI

In order to evaluate the predictive values of WC for MAU in patients at different levels of overweight/obesity, three tertials of WC were analyzed within each tertial of BMI. Within all three BMI groups, there was a graded increase in MAU from the low to the high WC tertial: MAU was present in 53.5% (95% CI: 52.0, 54.9) in the low versus 61.4% (95% CI: 56.6, 66.1) in the high WC tertial (1st BMI tertial, p < 0.0001), 54.8% (95% CI: 52.4, 57.2) in the low versus 62.1% (95% CI: 60.0, 64.2) in the high WC tertial (2nd BMI tertial, p < 0.0001) and 55.0% (95% CI: 49.7, 60.1) in the low versus 64.0% (95% CI: 62.7, 65.4) in the high WC tertial (3rd BMI tertial, p < 0.0001) (Figure 3).

Figure 3 Prevalence of MAU in relation to BMI & WC tertials.

Abbreviations: BMI, body mass index; MAU, microalbuminuria; WC, waist circumference.

Odds ratio for MAU according to BMI, WC alone, or in combination

In the univariate analysis, patients with a higher BMI had an increased risk of MAU with ORs ranging from 1.26 (95% CI: 1.19, 1.33) to 1.37 (95% CI: 1.28, 1.47) for the high versus low median or tertial, and 1.36 (95% CI: 1.26, 1.47) for obese patients (>30 kg/m²) versus those at normal weight (<25 kg/m²). Also patients with a higher WC are at an increased risk for MAU with an OR of 1.36 (95% CI: 1.29, 1.44) and 1.48 (95% CI: 1.38, 1.58) for the high versus low median or tertial. In men with a waistline >102 cm versus ≤102 cm, OR for MAU was 1.27 (95% CI: 1.18, 1.38), a finding which was also confirmed in women, where OR was 1.30 (95% CI: 1.19, 1.42) for a high (>88 cm) versus low waistline (>88 cm). Within each tertial of BMI, a high versus low waistline was associated with an increased risk of MAU, ranging from 1.38 (95% CI: 1.12, 1.69) for the 1st , to 1.47 (95% CI: 1.18, 1.82) for the 3rd BMI tertial (p < 0.0001) (see Figure 4a). In the multivariate analysis, an abnormal versus normal WC (defined as >102 cm versus ≤102 cm for men and >88 cm versus ≤88 cm for women), but not BMI, was independently associated with MAU (OR 1.132, 95% CI: 1.039, 1.233) (see Figure 4b).

Figure 4a Odds ratio for MAU for BMI, WC and BMI & WC (Univariate analysis).

Abbreviations: BMI, body mass index; CI, confidence interval; MAU, microalbuminuria; OR, odds ratio; WC, waist circumference.

Figure 4b Odds ratio for MAU for BMI & WC (Multivariate analysis).

Abbreviations: BMI, body mass index; CI, confidence interval; MAU, microalbuminuria; OR, odds ratio; WC, waist circumference.

Discussion

Excess in body fat mass can be measured by defining a subjects BMI (height-independent measure of weight), WC (marker of abdominal/viszeral excess fat) or waist-to-hip ratio (WHR; body shape in relation to fat deposition). An increase in BMI can indicate an increase in total body fat and has been shown not only to be linked with comorbidities such as hypertension, diabetes, coronary heart disease, but also with total mortality in men and women of different ethnic origin.^18–20 Its value in predicting cardiovascular risk has been challenged by the results of the INTERHEART Study.^11,21 According to this trial abdominal obesity, measured by WHR but less so by BMI, was shown to be an independent risk factor for the incidence of myocardial infarction. Our data from a large multiethnic sample of more than 20,000 hypertensive patients confirm that increases in BMI are associated with several important atherogenic risk factors, such as lack of exercise, dyslipidemia, total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, and presence of diabetes. Our data also clearly confirm the elevated risk profile of abdominally obese patients, by showing a higher overall prevalence of modifiable- and nonmodifiable risk factors in patients with an excess in abdominal fat. Beside these correlations, we sought to determine the risk of cardiovascular and renal end organ damage measured by MAU, an established surrogate marker of adverse cardiovascular and renal outcomes, and its correlation with different measures of obesity. In three small studies, no relationship between MAU and BMI, WC, WHR, or visceral obesity, measured by computed tomography, could be detected.^22–24 In contrast, analyses from the DCCT/EDIC (Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications) population in diabetic men and women showed that WHR, but not BMI, was associated with an abnormal urinary albumin excretion rate.^25,26 In our study, a linear relationship between BMI and MAU was detected in the univariate analysis: Across all categories of BMI, MAU prevalence increased significantly with BMI by absolute 8% from the 1st to 3rd tertial (Figure 1). In addition, WC showed a linear relationship with the prevalence of MAU, which increased by absolute 9% from the lowest to the highest WC tertial (Figure 2). Furthermore, these data show that within each BMI tertial, a high versus low WC appears to be associated with a higher MAU prevalence, supporting the notion of abdominal obesity confering an incremental risk for early renal and cardiovascular damage at any level of BMI.

In patients with abdominal obesity, a specific constellation of cardiovascular risk factors and markers, such as elevated blood pressure, low HDL-cholesterol, hypertriglyceridemia, elevated blood glucose, and insulin levels (impaired glucose tolerance) are clustered, findings which were confirmed by our data. This population shows a doubled risk for developing cardiovascular disease or diabetes.⁸ Moreover, recent data from similar populations demonstrated WC to be superior to BMI in predicting cardiovascular risk in men and women. Also in a recent analysis in 24,000 patients, WC was a better predictor for an increased risk of coronary artery disease than BMI,²⁷ results which were supported by the INTERHEART study indicating, that abdominal obesity measured by WHR represents an independent risk factor for the incidence of myocardial infarction.¹¹ We therefore also conducted a multivariate logistic regression analysis in order to evaluate the specific relationship of WC and BMI with MAU after adjustment for various confounding variables. In our multivariate model, WC, but not BMI, was identified as an independent marker of renal and cardiovascular risk by using MAU as a surrogate marker, thereby confirming the findings from INTERHEART and Canoy and colleagues^11,27 in this large sample of hypertensive patients.

At present, the specific pathophysiological link between obesity and MAU can only be speculated. Abdominal obesity represents a key component of the metabolic syndrome. The crucial components that may link abdominal obesity to other features of the metabolic syndrome and end-organ damage are presumably elevated insulin levels, peripheral tissue resistance to the insulin-sensitizing action of leptin, and increased macrophage infiltration in fat tissues with concomitant release of proinflammatory cytokines.^28,29 The described metabolic changes favor intracellular lipid deposition in adipose tissue, hepatocytes, skeletal and cardiac myocytes as well as in endothelial cells.^30,31 Intracellular fat deposits, associated with inflammatary cytokines and ischemia (pro-thrombotic state), frequently associated with abdominal obesity, might decrease the functional integrity of the endothelial wall and lead to MAU.

Taken together, the data presented from this large international cohort of hypertensive patients confirms the presence of an increased cardiovascular risk profile in patients with overweight and specifically abdominal obesity. Futhermore, a linear relationship of different measures of overweight/obesity with MAU, an established marker of cardiovascular disease and renal damage, was detected. However, only abdominal obesity, as measured by WC was independently associated with a higher prevalence of MAU. The data supports the current perception of the pathophysiological role of an excess in viszeral fat and underlines the importance of weight loss-efforts as essential goal in cardiovascular risk management and possibly also the prevention of renal damage.

Limitations

At present, it can only be speculated whether the observed relationship between overweight/obesity and MAU is similar across all ethnic groups included into the present analysis. However, since the study population was dominated by patients from western countries (about 15,500 patients), the conclusions mostly apply to Caucasian populations. For this reason, the present analysis also evaluated MAU in relation to specific cut-off levels of BMI and WC, recommended by international guidelines for this population. The main analysis was performed by a single dipstick screening test for MAU, where international guidelines recommend, that MAU should be established by three separate tests out of which two measurements should be positive. However, dipstick testing at one single occasion has been established as a usefull screening tool in epidemiological research.

Acknowledgments

JCR and MT contributed equally. The i-SEARCH program was supported by sanofiaventis. MB, MV, MT, and PB received support from sanofiaventis. MB and JCR are supported by the Deutsche Forschungsgemeinschaft (Klinische Forschergruppe KFO 196).